Lv2
120 积分 2024-04-03 加入
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
3天前
已完结
Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective
1个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
2个月前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
3个月前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
4个月前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
1年前
已完结
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
1年前
已完结
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
1年前
已完结
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
1年前
已完结
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
1年前
已完结
皖公网安备34019202002308
